Evaluating the Impact and Feasibility of Integrating Human Papillomavirus (HPV) Education Into Existing School-Based Health Education Initiatives in Cambodia and Kenya
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · Gates Foundation
OTHER · National Ethics Committee for Health Research, Cambodia
OTHER · National Ethics Committee for Health Research, Cambodia
OTHER · Amref Health Africa Ethics and Scientific Review Committee, Kenya
OTHER · National Commission for Science, Technology and Innovation (NACOSTI)
interventional
9,054
2 countries
5
Study Start
December 1, 2024
Actual (reported)Primary Completion
January 31, 2026
Actual (reported)Study Completion
January 31, 2026
Actual (reported)The Clinton Health Access Initiative conducted a mixed-methods, school-based interventional study in Cambodia and Kenya to evaluate whether integrating age-appropriate human papillomavirus (HPV) education into existing school health education improves HPV vaccination coverage and students' knowledge and awareness of HPV, HPV vaccination, and cervical cancer. The study also assessed HPV vaccine-related attitudes and the feasibility, acceptability, and cost of the integrated education model. Schools were assigned to intervention or control using setting-specific procedures that combined geographic structuring and random elements rather than uniform school-level randomization. Intervention schools received integrated HPV education, while control schools continued existing curricula without the study-added package. Routine HPV vaccination eligibility, products, schedules, supply, and delivery arrangements were unchanged. Quantitative outcomes were assessed at baseline and endline using school immunization records and repeated cross-sectional student knowledge, attitudes, and practices questionnaires. Qualitative interviews with caregivers, teachers, and healthcare workers examined HPV-related knowledge, vaccination perceptions, accessibility, and implementation feasibility and acceptability. A costing analysis estimated intervention cost per immunization administered. The study included 46 schools in Cambodia and 160 in Kenya.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 31, 2026
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 1, 2024
Actual (reported)January 31, 2026
Actual (reported)January 31, 2026
Actual (reported)August 14, 2026
Actual (reported)August 25, 2026
Actual (reported)HPV vaccination coverage among age-eligible girls
Proportion of age-eligible girls in participating schools with documented receipt of the HPV vaccine. Primary coverage analyses used school-based immunization records, supplemented by linked health-facility records in Kenya where school registers were unavailable; routine EPI/KHIS data were used for validation and sensitivity analyses. In Cambodia, coverage reflected receipt of the first dose under the national single-dose schedule among 9-year-old girls. In Kenya, the prespecified primary indicator was HPV vaccine dose 1 coverage among girls aged 10-14 years. Country-specific changes were compared between intervention and control schools using difference-in-differences analyses.
Baseline and endline (approximately 13 months after baseline in Cambodia and 9-10 months after baseline in Kenya)
HPV, HPV vaccine, and cervical cancer knowledge score among students
Mean composite knowledge score, expressed as a percentage, based on student KAP questionnaire items assessing cervical cancer, HPV, and HPV vaccination knowledge. Independent cross-sectional student samples were assessed at baseline and endline. Cambodia included Grades 3-5 at both rounds. Kenya included Grades 4-8 at baseline and Grades 5-9 at endline to reflect progression of the targeted grade cohorts. Country-specific changes were compared between intervention and control schools.
Participating schools received the existing school health/SRH curriculum plus integrated age-appropriate education on cervical cancer, HPV, and HPV vaccination delivered through routine school education activities. Cambodia implemented the integrated package in Grades 3-5 and Kenya in Grades 4-8.
Participating control schools continued the existing school health or sexual and reproductive health curriculum without the study-added integrated HPV education package. Routine HPV vaccination services continued according to existing national and local arrangements.
Age-appropriate cervical cancer, HPV, and HPV vaccination education was integrated into existing school health/SRH education and delivered by trained teachers. In Cambodia, the package comprised six approximately 45-minute sessions (three HPV-focused and three SRH-focused) for Grades 3-5. In Kenya, 25-35-minute health education sessions were delivered approximately 1-2 times per week over about 4.5 months to Grades 4-8, with HPV/SRH content prioritised and completed in approximately four sessions early in implementation. The study did not alter routine HPV vaccine products, eligibility, schedules, supply, or delivery arrangements.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Participating primary schools, Kampong Cham Province
Kampong Cham, Kampong Cham, Cambodia
Participating primary schools, Kratie Province
Kratie, Kratie, Cambodia
Participating primary schools, Kilifi County
Kilifi, Kilifi County, Kenya
Participating primary schools, Migori County
Migori, Migori County, Kenya
Participating primary schools, Nairobi County
Nairobi, Nairobi County, Kenya
Justin Graves, MPH
Clinton Health Access Initiative Inc.
Sonali Patel, MPA
Clinton Health Access Initiative Inc.
9,054 participants (actual enrollment reported by the registry).
First Submitted
Baseline and endline (approximately 9 months after baseline in Cambodia and 9-10 months after baseline in Kenya)
HPV awareness among students
Baseline and endline (approximately 9 months after baseline in Cambodia and 9-10 months after baseline in Kenya)
HPV vaccine awareness among students
Baseline and endline (approximately 9 months after baseline in Cambodia and 9-10 months after baseline in Kenya)
Motivation to receive HPV vaccination among girls
Baseline and endline (approximately 9 months after baseline in Cambodia and 9-10 months after baseline in Kenya)
Caregiver motivation to vaccinate an eligible child against HPV
Single post-intervention assessment, approximately 9 months after baseline in Cambodia and 5-6 months after baseline in Kenya
Caregiver social norms regarding HPV vaccination
Single post-intervention assessment, approximately 9 months after baseline in Cambodia and 5-6 months after baseline in Kenya
Perceived accessibility of HPV vaccination
Single post-intervention assessment, approximately 9 months after baseline in Cambodia and 5-6 months after baseline in Kenya
Feasibility and acceptability of integrating HPV education into school health education
Single post-intervention assessment, approximately 9 months after baseline in Cambodia and 5-6 months after baseline in Kenya
Cost per immunization administered under the intervention ACSM model
At intervention completion
Contact the study team to confirm eligibility.
August 14, 2026
First Posted
August 25, 2026
Study Start
December 1, 2024
Actual (reported)Primary Completion
January 31, 2026
Actual (reported)Study Completion
January 31, 2026
Actual (reported)Last Updated
August 25, 2026
Record last verified: 2026-08
De-identified individual-level student KAP data used in analyses reported in the primary peer-reviewed publication will be made publicly available in a publication-linked data repository, consistent with applicable ethical and privacy requirements. Direct identifiers and potentially identifying information will not be shared. Qualitative interview transcripts will not be included in the publicly shared IPD dataset.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: